Intervention Protocol

Adenosin-diphosphate (ADP) receptor antagonists (clopidogrel, ticlopidine) for the prevention of cardiovascular disease in type 2 diabetes mellitus

  1. Floris A Van de Laar1,*,
  2. Reinier P Akkermans2,
  3. Wim JC De Grauw2,
  4. Marcel MC Hovens3

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 24 MAY 2005

DOI: 10.1002/14651858.CD005449

Database Title

Additional Information

How to Cite

Van de Laar FA, Akkermans RP, De Grauw WJC, Hovens MMC. Adenosin-diphosphate (ADP) receptor antagonists (clopidogrel, ticlopidine) for the prevention of cardiovascular disease in type 2 diabetes mellitus (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005449. DOI: 10.1002/14651858.CD005449.

Author Information

  1. 1

    Radboud University Nijmegen Medical Centre, Department of General Practice, 117 HAG, Nijmegen, Netherlands

  2. 2

    Radboud University Nijmegen Medical Centre , Department of General Practice, 117 HAG, Nijmegen, Netherlands

  3. 3

    Rijnstate Hospital, Internal Medicine, Arnhem, Netherlands

*Floris A Van de Laar, Department of General Practice, 117 HAG, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Nijmegen, 6500 HB, Netherlands. f.vandelaar@cochraneprimarycare.org. f.vandelaar@hag.umcn.nl.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (134K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects of the use of ADP receptor antagonists on a regular basis on mortality and incidence of cardiovascular disease in patients with type 2 diabetes mellitus.

View Full Article (HTML) Full (134K)